Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.
2026 · 1st Quarter (Jan 1 - Mar 31)
OBJECT PHARMA
Filed by EAGLE POINT STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 13, 2026
- Income
- $10,000.00
- Expenses
- Not reported
- Registrant
- EAGLE POINT STRATEGIES LLC
- Client
- OBJECT PHARMA
- Filing UUID
- 158e9b08-42da-49b5-adb1-7d61eb376788
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.